Dr. Jacques Brown graduated from medical school and completed his residency in Internal Medicine at Laval University. He finished his residency in rheumatology at Université de Sherbrooke before undertaking post-doctoral training in metabolic bone diseases at the INSERM unit in Lyon, France.
He is a clinical researcher at the Centre de recherche du CHU de Québec-Laval University and a clinical professor at the Department of Medicine at Laval University. His major research interest is metabolic bone disorders such as Paget’s disease of bone, and osteoporosis.
Through the characterization of three French-Canadian families with Paget’s disease of bone, he first contributed to the discovery (2001) of the SQSTM1 gene mutations linked to this disease. In collaboration with Dr. Laëtitia Michou, this cohort now contains 43 families, 263 unrelated individuals with Paget’s disease and 298 controls, totalling 1,426 DNA samples with detailed phenotypes. The recruitment of new families and unrelated patients continues to help better identify new genetic factors of Paget’s disease of bone.
Since 1994, he has been a co-principal investigator and Quebec Centre Director on the Canadian Multicentre Osteoporosis Study (CaMOS), an epidemiologic study looking at the prevalence of osteoporosis, as well as the incidence of osteoporotic fractures in a large cohort (9,400 subjects) of the Canadian population. He is the principal investigator of the Recognizing Osteoporosis and its Consequences Programme, a patient health-management programme aimed at evaluating the diagnostic and treatment care gaps for osteoporosis following a fragility fracture in women 50 years of age and over.
He has published over 240 scientific articles in several high-impact journals. He has received several distinctions, including two John G. Haddad Jr. Research Awards from the Paget’s Foundation (2003 and 2005) and the Lindy-Fraser Memorial Award from Osteoporosis Canada (2004) for his work on the clinical practice guidelines of osteoporosis. In 2009, he was knighted to the Ordre National du Québec. More recently, Dr. Brown received the 2017 Distinguished Investigator Award from the Canadian Rheumatology Association for his exceptional contribution to rheumatology in Canada, and the Council of Physicians, Pharmacists, and Dentists of the CHU de Québec has awarded him the Diamant Hommage Héritage for the development and accomplishment of his career which will leave a solid legacy for the future of the institution.
2705, boulevard Laurier
TR-83
Québec, Québec
Canada G1V 4G2
Latest news
Data not available
- Beaudoin, ClaudiaDoctoral studentHôpital de l'Enfant-Jésus+1 418-649-0252claudia.beaudoin.1@ulaval.caClaudia.Beaudoin@crchudequebec.ulaval.ca
1401, 18e Rue
Québec, Québec
Canada G1J 1Z4
Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada.
Journal ArticleBMC Musculoskelet Disord, 22 (1), pp. 224, 2021.
Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada.
Journal ArticleOsteoporos Int, 2021, ISSN: 0937-941X.
Vertebral Fractures: Which Radiological Criteria Are Better Associated With the Clinical Course of Osteoporosis?
Journal ArticleCan Assoc Radiol J, 72 (1), pp. 150-158, 2021, ISSN: 0846-5371.
Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario.
Journal ArticleBMC Musculoskelet Disord, 22 (1), pp. 105, 2021.
Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study.
Journal ArticleOsteoporos Int, 2021, ISSN: 0937-941X.
Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture.
Journal ArticleJ Bone Miner Res, 2021, ISSN: 0884-0431.
A scorecard for osteoporosis in Canada and seven Canadian provinces.
Journal ArticleOsteoporos Int, 32 (1), pp. 123-132, 2021, ISSN: 0937-941X.
Clinical phenotype of adult offspring carriers of the p.Pro392Leu mutation within the SQSTM1 gene in Paget's disease of bone.
Journal ArticleBone Rep, 13 , pp. 100717, 2020, ISSN: 2352-1872.
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.
Journal ArticleOsteoporos Int, 31 (11), pp. 2231-2241, 2020, ISSN: 0937-941X.
Vertebral Fractures: Which Radiological Criteria Are Better Associated With the Clinical Course of Osteoporosis?
Journal ArticleCan Assoc Radiol J, pp. 846537120963692, 2020, ISSN: 0846-5371.
Active projects
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Recently finished projects
- Clinical validity and clinical utility of a screening test for Paget's disease of bone, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-03-01 to 2020-03-31